Abstract
This chapter begins with an overview of pain concepts, pain scoring, and analgesic options. It goes on to review current treatment suggestions for the ballistic casualty at each stage of their care. Finally, a series of appendices offer further information on the drugs, on patient controlled devices, and management of overdoses. Note: Medication regulatory issues vary around the world and are beyond the scope of this text. Therefore, these issues will not be discussed.
Keywords
- Pain Management
- Compartment Syndrome
- Regional Anesthesia
- Patient Control Analgesic
- Peripheral Nerve Block
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Luger TJ, Lederer W, Gassner M, Lockinger A, Ulmer H, Lorenz IH. Acute pain is underassessed in out-of-hospital emergencies. Acad Emerg Med. 2003;10(6):627-632.
Bricknell MC, Hanhart N. Stability operations and the implications for military health services support. J R Army Med Corps. 2007;153(1):18-21.
Joshi GP, Ogunnaike BO. Consequences of inadequate postoperative pain relief and chronic persistent postoperative pain. Anesthesiol Clin N Am. 2005;23(1):21-36.
Merskey H, Bogduk N. In: Merskey H, Bogduk N, eds. Classification of Chronic Pain. 2nd ed. 1994.
Collins SL, Moore RA, McQuay HJ. The visual analogue pain intensity scale: what is moderate pain in millimetres? Pain. 1997;72(1–2):95-97.
Markowitz J. A series of over 100 amputations of the thigh for tropical ulcer. J R Army Med Corps. 1947;86:159-170.
Baker BC, Buckenmaier C, Narine N, Compeggie ME, Brand GJ, Mongan PD. Battlefield anesthesia: advances in patient care and pain management. Anesthesiol Clin. 2007;25(1):131-145. x.
Kotwal RS et al. Novel pain management strategy for combat casualty care. Ann Emerg Med. 2004;44:121-127.
Mabry R, McManus JG. Prehospital advances in the management of severe penetrating trauma. Crit Care Med. 2008;36(Suppl):S258-S266.
Rivara FM, MacKenzie EJ, Avery B, Nathens M, Jin Wang, Daniel OS. Prevalence of pain in patients 1 year after major trauma. Arch Surg. 2008;143(3):282-287.
Administration FD. Use of Codeine Products in Nursing Mothers. 2008 [updated 2008; cited 2008, 25 Aug 08]; Available from: http://www.fda.gov/cder/drug/infopage/codeine/default.htm.
Malchow RW, Black I. The evolution of pain management in the critically ill trauma patient: emerging concepts from the global war on terrorism. Crit Care Med. 2008;36(Suppl):S346-S357.
McLennan JV. Is methoxyflurane a suitable battlefield analgesic? J R Army Med Corps. 2007;153(2):111-113.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Appendices
Appendix I: Medication Review
These are not comprehensive instructions and no responsibility can be taken for doses suggested.
-
Non Steroidal Anti Inflammatory Drugs (NSAIDs)
-
Diclofenac
-
Ibuprofen
-
Specific COX II Inhibitors.
-
-
Opioids
-
Morphine
-
Pethidine
-
Fentanyl
-
Alfentanil
-
Remifentanil
-
Methadone
-
Hydromorphone
-
Weak Opioids
-
Codeine
-
Tramadol
-
Buprenorphine
-
-
-
Other Analgesics
-
Ketamine
-
Paracetamol
-
Methoxyflurane
-
Entonox
-
-
Peripheral Nerve Blocks
1.1 Non Steroidal Anti Inflammatory Drugs (Nsaids)
1.1.1 Mechanism
NSAIDs work by inhibiting the action of the enzyme cyclooxygenase. This prevents the production of a number of substances that are thought to produce pain as well as a number of other actions.
1.1.2 Effects
In addition to their analgesic and antipyretic actions NSAIDs are associated with a number of other effects.
1.1.2.1 Gastric Irritation
This can result in a spectrum of problems from mild pain to fatal hemorrhage. This side effect is thought to be reduced with the use of COX II inhibitors.
1.1.2.2 Inhibition of Coagulation
This is predominately through inhibition of platelet function although may be less with COX II inhibition.
1.1.2.3 Inhibition of Renal Function
Renal prostaglandin production may be reduced by NSAID administration. This can lead to a critical reduction in renal blood flow which in the presence of hypotension and hypovolaemia can lead to acute renal failure.
1.1.2.4 Inhibition of Bone Repair
This may be significant in long term use delaying fracture repair.
1.1.2.5 NSAID Sensitive Asthma
Up to 20% of asthmatics may experience a severe asthma attack on exposure to NSAIDs. Children appear to be relatively protected from this. These are associated with allergic rhinitis, nasal polyps, and middle aged asthma sufferers.
1.1.3 Agents
1.1.3.1 Diclofenac
Routes | Oral, intravenous and rectal |
Doses | Adults 150 mg daily. |
1.1.3.2 Ibuprofen
Of the most commonly used NSAIDs ibuprofen has the lowest rate of gastric side effects. This may be in part due to its having the weakest anti inflammatory properties – it does not follow that it necessarily has the weakest analgesic actions.
Routes | PO. peak analgesia being reached in 1–2 h. |
Doses | Adult – 1,800 mg daily in 4–6 divided doses. Paeds – 5 mg/kg QDS |
1.1.3.3 Ketorolac
Potent NSAID with advantage of having an intravenous formulation. Should be used with great caution in renal compromise. Doses range from 15–30 mg IV.
1.1.3.4 Specific COX II Inhibitors
These are thought to reduce the incidence of gastric complications and reductions in platelet function. Their use is also subject to “guidance” from a number of regulatory bodies and it is likely that their use will continue to change with time. Examples include celecoxib and paracoxib.
1.1.4 Opioids
1.1.4.1 Introduction
The term “opiate” refers to naturally occurring substances with morphine like properties whilst “opioid” includes the synthetic analgesics that act via the opioid receptors and are competitively antagonized by naloxone.
An important factor to consider when administering opioids is that individual dose requirements will vary between patients and even for the same patient on different occasions just as pain vaires. For this reason the best approach is to titrate the dose administered according to patient requirement. In this way one can achieve optimum analgesia with the minimum of side effects.
1.1.5 Strong Opioids
1.1.5.1 Morphine
The “gold standard” analgesic
1.1.5.1.1 Effects
-
1.
Cental Nervous System
-
Analgesia
-
Sedation, followed by euphoria and then dysphoria with increasing dose
-
Meiosis, a result of Edinger – Westphal nucleus stimulation
-
Nause and Vomiting – the chemoreceptor trigger zone may be indirectly simulated but the vomiting center is not. In fact higher doses may inhibit the system so as to reduce nausea and vomiting.
-
Hallucinations in c. 3%
-
-
2.
Respiratory System
-
Respiratory depression
-
Antitussive effect
-
Bronchospasm can occur, usually a result of histamine release.
-
-
3.
Cardiovascular System
-
Histamine release is thought to result in a reduction in smooth muscle tone and a mild bradycardia.
-
-
4.
Gastrointestinal
-
Gut sphincters contract and motility is reduced leading to constipation and possibly increased vomiting.
-
-
5.
Genitourinary
-
Increased tone of the detrusor and sphincter muscles may precipitate urinary retention.
-
-
6.
Musculoskeletal
-
Opioids can increase muscle rigidity. This appears to be more common following rapid intravenous administration rather than by other routes.
-
-
7.
Skin
-
Puritis, most marked with epidural or intrathecal routes. Antihistamines may help although the role of histamine is uncertain.
-
-
8.
Endocrine
-
ADH secretion is increased which may lead to impaired water excretion and hyponatraemia
-
Routes | Multiple routes possible, including intranasal. The subcutaneous route is not encouraged because of relatively low lipid solubility. |
Following intramuscular administration peak analgesia should be reached after c.10–30 min and may last 4 h. In the normal patient this is almost as as fast an onset as the intravenous route. | |
Orally it has a 50% bioavailability. | |
Morphine undergoes extensive biotransformation to active metabolites. Problems can be caused with renal failure causing reduced elimination. | |
Dose | The difficulty is that morphine the dose that can be given will depend upon the pain the patient experiences. There is no clear “upper limit.” |
An initial dose of 0.05–0.1 mg/kg iv or im should be used to start analgesia. | |
In adults 2 mg iv every 5 min to titrate analgesia after an initial bolus. | |
10 mg im can be repeated every 2 h although under appropriate supervision more than this may be required. |
1.1.5.2 Pethidine
It is available as tablets and solution for injection. It is said to produce less biliary tract spasm than morphine although the clinical significance of this is often questioned.
Serious interaction is seen with monoamine oxidase inhibitors including coma, labile circulation, convulsions, and hyperpyrexia.
Anticholinergic effects such as a dry mouth and occasional tachycardia can occur.
It is inactivated in the liver to a number of metabolites including norpethedine which has half the analgesic activity of pethidine, a longer elimination half-life, an association with hallucinations and grand mal seizures, and effects not reversed by naloxone.
Routes | PO IV, IM |
Dose | 0.5–1 mg/kg, titrated to effect. |
1.1.5.3 Fentanyl
A clear colorless intravenous solution also available in the form of transdermal patches, buccal and sublingual tablets, and a buccal “lollipop.”
An iontophoretic “PCA” patch is available.
It has negligible oral bioavailability which means that fentanyl has to be absorbed through the oral mucosa rather than “swallowed.”
One vital point to note when using this buccal route is that the lozenge has to “paint” the oral mucosa and not sit statically on one site if the drug is to be optimally absorbed. Tablet forms are now available for sublingual and buccal use that do not require this movement.
Fentanyl is said to release less histamine than morphine thus may not reduce blood pressure to the same degree (Fig. 20.2).
Dose | IV: 1 μ(mu)g/kg. |
Oral “lollipop”: Approximately 10–1 ratio with intravenous morphine (thus 800 μ(mu)g oral transmucosal fentanyl ≈ 8 mg iv morphine).10 |
1.1.5.4 Alfentanil
This is an opioid that is only really used for sedation and perioperative analgesia.
1.1.5.5 Remifentanil
It is a potent analgesic that will only be used perioperatively or for sedation.
1.1.5.6 Methadone
This is a synthetic opioid which is used in some parts of the world for the management of acute pain. It is thought to have a wide range of actions and not solely opioid in nature as it may have activity at NMDA receptors. It also has a long half-life.
1.1.5.7 Hydromorphone
Thought to have a swifter onset than morphine. Approximately four times more potent orally and eight times more potent via the parenteral route.
1.1.6 Weak Opioids
1.1.6.1 Codeine
It is approximately one sixth the potency of morphine. It is relatively more effective orally than parenterally.
Intravenous route tends to be avoided because of incidents of hypotension.
It has been suggested codeine is just a prodrug for morphine. However, approximately 9% of the UK population is poor metabolizers of codeine. This may often result in significantly reduced analgesia in this population. Conversely some people may be very good metabolizers and have an excessive response.11
Dose | Adult- 30–60 mg QDS; but more may be necessary. |
1.1.6.2 Tramadol
Tramadol is described as a “weak” opioid and is indicated for the treatment of moderate to severe pain.
The effects are similar to those of morphine. It may make epilepsy more common in those that are susceptible to it.
It should not be given with monoamine oxidase inhibitors.
Dose | Up to 400 mg daily in divided doses. |
1.1.6.3 Buprenorphine
Thought to be 30 times more potent than morphine. There have been suggestions that it is less likely to cause respiratory depression. However even high doses of naloxone have difficulty in antagonizing its actions.
Anecdotal reports suggest nausea and vomiting may be more common with buprenorphine than other opioids.
Routes | Sublingual, injection (im & iv) |
Dose | Sublingual: 200–400 μg QDS |
Intramuscular/slow intravenous: 300–600 μg QDS
1.1.7 Other Analgesics
1.1.7.1 Ketamine
Ketamine is a relatively unique drug that, like opioids, causes a range of actions from dysphoria and analgesia to death. However it is not an opioid but a phencyclidine derivative.
There is a belief that the stereoselective isomer has a better side effect profile than the racemic mixture but it is the latter that one finds more often.
The traditional use of ketamine was limited to use as an anesthetic agent in the hemodynamically unstable trauma patient. The US Army has been able to frequently utilize subanesthetic doses of ketamine in low rate continuous infusions and PCA combinations in perioperative and acute pain management. Advantages to the use of ketamine in this context have been a reduction in opioids required to reach a given level of pain relief, decreased risk of respiratory depression, reduction of the development of opioid tolerance, prevention of opioid-induced hyperalgesia, and although controversial, reduction of risk of chronic pain.12
1.1.8 Effects
1.1.8.1 CNS
The anesthesia produced is typically described as “dissociative anesthesia.”
Limb movement may occur as may groaning. These do not necessarily indicate a light anesthetic.
Sedation occurs in sub-anesthetic doses in common with analgesia.
Dreaming and hallucinations occur especially on emergence and during sedation. These can be vivid and worrying and are more common in adults than children. They may be reduced with concomitant administration of opiates or benzodiazepines.
Consequently the issue of ketamine use in the head injured patient is being reviewed.
There can be preservation of corneal and light reflexes together with slow nystagmic gaze.
1.1.8.2 Respiratory System
Respiratory function is relatively well preserved as are airway reflexes. Ketamine is acts as a bronchodilatator.
An increase in salivary and tracheobronchial secretions occurs and this may be problematic.
1.1.8.3 Cardiovascular
Ketamine is a potent sympathomimetic. This action tends to mask its myocardial depressant and venodilatation actions, certainly on initial dosage. Myocardial depression is less with ketamine than it is with other intravenous anesthetic agents.
Routes | Intravenous and intramuscular routes remain the military routes of choice at present. Intranasal route may have some uses. Intramuscular Ketamine has a peak plasma level of about 20 min. |
Doses | Analgesia and sedation is usually to be found using subanesthetic doses; low infusion rates for analgesia range from 0.5–2mcg/kg/min; infusion for sedation for painful procedures ranging from 5–10mcg/kg/min; PCA mixtures most commonly 1 mg morphine/1 mg ketamine; 10–20 mg bolus aliquots titrated for effect and repeated as required. |
1.1.8.4 Paracetamol
In common with many other NSAIDS paracetamol is freely available over the counter either alone or in combination with a number of other drugs. For this reason, as mentioned above, there is a real possibility of overdose, either deliberate or accidental. Commonly described as having “synergy” with other analgesics with approximate 20% opioid-sparing analgesic properties.
1.1.9 Effects
1.1.9.1 CNS
The exact site of paracetamol’s action is still under debate but as well as being an analgesic it also has good antipyretic properties.
1.1.9.2 GI
Unlike traditional NSAIDs paracetamol is not thought to have an irritant effect on the gastric mucosa.
1.1.9.3 GU
In overdose there is a risk of renal tubular necrosis.
1.1.9.4 Methoxyflurane
This is an inhaled anesthetic vapor that in low doses gives good pain relief. It is in use with the Australian and New Zealand Defence Forces. However there are side effects and complications associated with it that make its use in British forces unlikely.13
1.1.9.5 Entonox
This is mixture of oxygen and nitrous oxide. Again it requires a degree of coordination to allow inhalation. It requires a relatively bulky apparatus to provide it. There are also practical issues surrounding its use and storage that make it unattractive for use in the prehospital environment. Below − 6°C, the pseudocritical temperature of entonox, the mixture undergoes lamination and nitrous oxide enters the liquid phase. Thus initially oxygen alone is delivered and then only nitrous oxide. It should also be avoided in patients with bowel obstruction, pneumothorax, sinus, and middle ear disease.
1.1.9.6 Peripheral Nerve Blocks
In depth discussion on the use of peripheral nerve blocks is outside the scope of this chapter.
Limb blocks are the most common blocks used. They can be either as “single shot” injections or as infusions. They may be done “blind” or guided using peripheral nerve stimulators or even ultrasound.
Appendix II: Patient Controlled Analgesia
2.1 Introduction
As the name suggests, this is a technique by which the patient is able to control the administration of their analgesia.
The current British military device is the Baxter “Wristwatch” PCA. US forces have utilized several different PCA pumps (most commonly the Sorenson “Ambit”) which have also been utilized for continuous peripheral nerve blockade. There has been effort to switch to a separate, color-coded, standardized pump for each use to avoid confusion.
Typically morphine 2 mg/ml is the solution used with this system. The addition of an antiemetic to this solution is not encouraged.
This system does not provide a one-stop solution to the problems of analgesia for all patients, and it does not transfer all responsibility for analgesia to the patient but it may help reduce nursing workload. However, the patient does need to be monitored by the ward staff to confirm efficacy, and watch for unwanted side effects from the morphine. To aid this it is normal practice for a suitable protocol to be employed on the wards and an example of this is given below.
The fentanyl iontophoretic patch PCA, “Ionsys” does exist but at present there are no plans for its widespread use within the military system.
2.2 PCA Protocol
Patient suitability is determined by an anesthetist or the acute pain team in conjunction with ward staff.
The PCA must be prescribed on a suitable drug prescription chart. This does not prevent the prescription of other analgesics although care should be taken with alternative medication that may augment unwanted side effects of the morphine.
Regular recordings of pulse, blood pressure, respiratory rate, pain, and sedation (see below) are required. Typical timings are:
-
Recovery – 5 min. To include SpO2 until stable.
-
Ward – hourly for 4 h and then 4 hourly.
However, if the PCA was started on the ward then as for recovery for the first hour.
2.3 Pain and Sedation Score
Appendix III: Oxygen Administration Protocol
Patients who have one of the following signs should be given supplementary oxygen:
-
SpO2 < 95% on air
-
Sedation score of 3 (see pca protocol for scoring scale)
-
Respiratory rate < 9/min
Oxygen should be started at 4l/min via a mask immediately.
Regular recordings of pulse rate, respiratory rate, blood pressure, SpO2, and sedation should be initiated.
Refer to the Opiate Overdose Protocol if this is thought to be the origin of the respiratory depression.
The medical staff should be informed as soon as possible.
Ensure the location of the resuscitation equipment is confirmed.
Appendix IV: Protocol Opiate Overdose
Typical signs are:
-
Respiratory rate < 9
-
Sedation score of 3 (severely sedated, difficult to rouse)
-
Reduced SpO2
Prompt intervention is required to prevent a potentially threatening event occurring.
If opiate overdose is suspected:
-
Give oxygen, according to the Oxygen Administration. Protocol
-
Give Naloxone 0.4 mg iv bolus. This may need to be repeated after 10–15 min.
-
Inform the medical staff as soon as possible.
Appendix V: Paracetamol Overdose
As little as 5 g of paracetamol taken in a 24 h period may lead to severe hepatic damage. This damage is maximal after 3–4 days but initial symptoms may be sufficiently mild as to not cause undue concern.
Actual plasma paracetamol levels may be difficult to obtain in field conditions. However, if 150 mg/kg has been taken with the last hour administration of activated charcoal is suggested. Antidotes such as acetylcysteine and methionine may protect the liver if given within 12 h of ingestions, although the former may be protective up to 24 h after ingestion.
Appendix VI: UK : US Drug Names
Often US generic drug names will be different to UK names. Almost always the Brand name will be different and these are used more often in the US than the UK.
This list is not exhaustive (Table 20.4).
Rights and permissions
Copyright information
© 2011 Springer London
About this chapter
Cite this chapter
Nelson, A.D., Aldington, D.J. (2011). Battlefield Analgesia. In: Brooks, A., Clasper, J., Midwinter, M., Hodgetts, T., Mahoney, P. (eds) Ryan's Ballistic Trauma. Springer, London. https://doi.org/10.1007/978-1-84882-124-8_20
Download citation
DOI: https://doi.org/10.1007/978-1-84882-124-8_20
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-84882-123-1
Online ISBN: 978-1-84882-124-8
eBook Packages: MedicineMedicine (R0)